First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)—a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG-Reference-Cited by-同舟云学术

First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)—a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG

Published:2012-10 Issue:10 Volume:23 Page:2613-2619
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Lindemann K.,Christensen R.D.,Vergote I.,Stuart G.,Izquierdo M.A.,Kærn J.,Havsteen H.,Eisenhauer E.,Ridderheim M.,Lopez A.B.,Hirte H.,Aavall-Lundquvist E.,Vrdoljak E.,Green J.,Kristensen G.B.

Funder

Pharmacia-Upjohn

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/23/10/2613/13786356/mds060.pdf

Reference23 articles.

1. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004);du Bois;Ann Oncol,2005

2. Meta-analysis of cisplatin, doxorubicin, and cyclophosphamide versus cisplatin and cyclophosphamide chemotherapy of ovarian carcinoma;Fanning;Obstet Gynecol,1992

3. Impact of doxorubicin on survival in advanced ovarian cancer;A'Hern;J Clin Oncol,1995

4. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. The Ovarian Cancer Meta-Analysis Project;The Ovarian Cancer Meta-Analysis Project;J Clin Oncol,1991

5. A phase II study of high-dose epirubicin in ovarian cancer patients previously treated with cisplatin;Vermorken;Ann Oncol,2000

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Deciphering the Molecular Mechanisms behind Drug Resistance in Ovarian Cancer to Unlock Efficient Treatment Options;Cells;2024-05-04

2. A signature of circulating miRNAs predicts the prognosis and therapeutic outcome of taxane/platinum regimen in advanced ovarian carcinoma patients;Clinical and Translational Oncology;2024-03-12

3. Upregulation of CALD1 predicted a poor prognosis for platinum-treated ovarian cancer and revealed it as a potential therapeutic resistance target;BMC Genomics;2024-02-16

4. Exploring the tumor immune microenvironment in ovarian cancer: a way-out to the therapeutic roadmap;Expert Opinion on Therapeutic Targets;2023-09-02

5. Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysis;European Journal of Cancer;2023-09